Table 6.

The effect of nano and bulk forms of aspirin and ibuprofen on the lymphocytes from patient groups and healthy individuals compared to untreated lymphocytes in the micronucleus assay.

Subject	Treatment	% BiNC	% Multi	MNi in BiNC cells			Mono
				BiMNi	BiNPB	BiBuds	MNi
Healthy individuals	Untreated lymphocytes	50.025 ± 2.02	28.52 ± 0.56	6.00 ± 1.02	3 ± 0.02	0	0
	Positive control	59.12 ± 4.07	13.49 ± 0.44	47.75 ± 0.25	1.75 ± 0.77	1.25 ± 0.5	11.75 ± 1.32
	Aspirin—B	53.775 ± 2.03	24.83 ± 1.52	5.22 ± 0.16	1.25 ± 0.04	0	3.5 ± 0.02
	Aspirin—N	59.55 ± 0.06	13.55 ± 1.09	4 ± 0.03	0.25 ± 0.02	0	1 ± 0.45
	Ibuprofen—B	57.8 ± 1.86	15.9 ± 0.09	5.75 ± 0.14	1 ± 0.125	0	2 ± 0.02
	Ibuprofen – N	54.91 ± 2.09	31.56 ± 1.62	4.5 ± 0.06	1 ± 0.4	0	1.5 ± 0.3
Asthma	Untreated lymphocytes	42.04	36.16	4	0	0	0
	Positive control	44.17	39.16	19	0	0	4
	Aspirin—B	42.44	29.05	5	1	1	1
	Aspirin—N	50.1	16.11	2	1	0	4
	Ibuprofen—B	47.5	25.14	8	0	2	0
	Ibuprofen—N	52.13	28.2	6	0	0	4
COPD	Untreated lymphocytes	57.42	2	10	0	0	1
	Positive control	25.4	0.3	17	0	2	1
	Aspirin—B	48.5	0.5	13	0	0	4
	Aspirin—N	45.22	0.3	10	0	0	1
	Ibuprofen—B	41.43	0.2	14	0	0	9
	Ibuprofen—N	45.02	0.1	16	0	0	1
Lung cancer	Untreated lymphocytes	46.33 ± 4.40	35.34 ± 0.48	22.67 ± 2.06	5.21 ± 0.22	3.33 ± 1.24	14.66 ± 4.01
	Positive control	44.66 ± 0.06	35.66 ± 0.02	32.33 ± 0.34	2.23 ± 0.12	5.33 ± 0.04	2.00 ± 0.01
	Aspirin—B	43.33 ± 0.07	29.33 ± 0.67	15.66 ± 2.77	3.33 ± 0.08	4.66 ± 0.26	3.00 ± 0.03
	Aspirin—N	45.00 ± 0.12	29.66 ± 0.27	7.66 ± 0.02	0	2.33 ± 0.33	2.6 ± 0.63
	Ibuprofen—B	42.33 ± 0.34	27.33 ± 0.05	11.00 ± 0.03	2.33 ± 0.01	3.66 ± 0.04	9.33 ± 0.15
	Ibuprofen—N	47.33 ± 0.01	29.00 ± 0.12	9.00 ± 0.14	1.33 ± 0.56	0	2.66 ± 0.05

BiNC, Binucleated cells, % BiNC, is % expressed out of all types of 1000 (500 × 2) cells scored; MonoNC, Mononucleated cells; MultiNC, Multinucleated cells % MultiNC, is % expressed out of all types of 500 cells scored; MNi, Micronuclei score/1000 (500 × 2) cells each of BiNC and MonoNC.